Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

Related Keywords

Texas ,United States ,Hagopm Kantarjian , ,Department Of Leukemia ,University Of Texas Md Anderson Cancer Center ,Samsung Distinguished Leukemia Chair ,Cancer Medicine ,Society Of Hematologic Oncology Annual Meeting Soho ,Hematologic Oncology ,Conference ,Precision Medicine In Oncology ,Ponatinib ,Iclusig ,Nct01207440 ,2023 Soho Annual Meeting ,Chronic Myeloid Leukemia ,